Stacey Nee Macfarlane

Array ( [id] => 19125718 [patent_doc_number] => 20240131071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES [patent_app_type] => utility [patent_app_number] => 18/546141 [patent_app_country] => US [patent_app_date] => 2022-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125718 [patent_doc_number] => 20240131071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES [patent_app_type] => utility [patent_app_number] => 18/546141 [patent_app_country] => US [patent_app_date] => 2022-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19550188 [patent_doc_number] => 12133880 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => Compositions and methods for treatment of GCase related disease states [patent_app_type] => utility [patent_app_number] => 17/680375 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 53 [patent_no_of_words] => 8027 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457711 [patent_doc_number] => 12098191 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Antibodies to amyloid beta [patent_app_type] => utility [patent_app_number] => 17/673449 [patent_app_country] => US [patent_app_date] => 2022-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 49886 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642245 [patent_doc_number] => 20220169983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/671430 [patent_app_country] => US [patent_app_date] => 2022-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17671430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17579120 [patent_doc_number] => 20220135975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => INHIBITION OF LET7I AS A MEANS TO ENHANCE THE PROTECTIVE EFFECT OF PROGESTERONE AGAINST STROKE [patent_app_type] => utility [patent_app_number] => 17/580689 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17580689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578806 [patent_doc_number] => 20220135661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => Monoclonal Antibodies Against Alpha-Synuclein Fibrils [patent_app_type] => utility [patent_app_number] => 17/572309 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17572309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955202 [patent_doc_number] => 20240043529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => METHODS AND COMPOSITIONS RELATED TO BCL2 AND BIM HETERODIMER ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/269036 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17534712 [patent_doc_number] => 20220113321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => NEURAL PROTEINS AS BIOMARKERS FOR NERVOUS SYSTEM INJURY AND OTHER NEURAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/560144 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112864 [patent_doc_number] => 20240124614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/269099 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 536 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18863301 [patent_doc_number] => 20230417737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => IN VITRO METHOD FOR FUNCTIONAL ASSESSMENT OF HAEMATOPOIETIC PROGENITORS [patent_app_type] => utility [patent_app_number] => 18/254699 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505448 [patent_doc_number] => 20220098550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHOD FOR MANUFACTURING TELENCEPHALON OR PROGENITOR TISSUE THEREOF [patent_app_type] => utility [patent_app_number] => 17/549468 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861917 [patent_doc_number] => 20230416352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING ANTI-CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/039683 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 268 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879172 [patent_doc_number] => 20240002541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => METHODS AND MATERIALS FOR TREATING T CELL CANCERS [patent_app_type] => utility [patent_app_number] => 18/039403 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902763 [patent_doc_number] => 20240018248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER [patent_app_type] => utility [patent_app_number] => 18/255433 [patent_app_country] => US [patent_app_date] => 2021-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20218601 [patent_doc_number] => 20250281532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => METHODS FOR DIAGNOSING OR TREATING HEALTH CONDITIONS OR OPTIMIZING THERAPEUTIC EFFICACY OF CAR-T CELLS THERAPIES [patent_app_type] => utility [patent_app_number] => 18/251697 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860225 [patent_doc_number] => 20230414659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => METHODS OF ADMINISTERING GENETICALLY MODIFIED B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/034865 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18818808 [patent_doc_number] => 20230393148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => KITS, REAGENTS AND METHODS FOR THE ASSESSMENT OF LIVER DISEASES [patent_app_type] => utility [patent_app_number] => 18/034329 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578804 [patent_doc_number] => 20220135659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => TREATMENT OF NEONATAL HYPOXIA INCLUDING IMPAIRMENTS OR EFFECTS THEREOF [patent_app_type] => utility [patent_app_number] => 17/504085 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17549394 [patent_doc_number] => 20220120735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Testing Methods for Determination of T2R Phenotype and Applications Thereof [patent_app_type] => utility [patent_app_number] => 17/500755 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500755 [rel_patent_id] =>[rel_patent_doc_number] =>)